Other research analysts also recently issued reports about the company. ValuEngine downgraded Revance Therapeutics from a hold rating to a sell rating in a report on Tuesday, July 2nd. Barclays initiated coverage on Revance Therapeutics in a report on Tuesday, June 11th. They set an overweight rating and a $28.00 price objective on the stock. Finally, Mizuho restated a buy rating and set a $37.00 price objective on shares of Revance Therapeutics in a report on Wednesday, April 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company. Revance Therapeutics presently has a consensus rating of Buy and an average price target of $33.09.
Shares of NASDAQ RVNC traded down $0.29 during midday trading on Wednesday, hitting $12.27. The company’s stock had a trading volume of 298,611 shares, compared to its average volume of 353,985. The company has a current ratio of 8.13, a quick ratio of 8.13 and a debt-to-equity ratio of 0.13. The business’s 50 day moving average price is $12.23. Revance Therapeutics has a 12-month low of $10.37 and a 12-month high of $29.90. The firm has a market capitalization of $553.60 million, a price-to-earnings ratio of -3.11 and a beta of 1.00.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its holdings in shares of Revance Therapeutics by 21.7% in the 4th quarter. Legal & General Group Plc now owns 6,445 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 1,150 shares during the period. Edge Wealth Management LLC increased its holdings in shares of Revance Therapeutics by 550.0% in the 1st quarter. Edge Wealth Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock valued at $51,000 after acquiring an additional 2,750 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of Revance Therapeutics in the 2nd quarter valued at $37,000. Swiss National Bank increased its holdings in shares of Revance Therapeutics by 5.6% in the 2nd quarter. Swiss National Bank now owns 73,350 shares of the biopharmaceutical company’s stock valued at $951,000 after acquiring an additional 3,900 shares during the period. Finally, Rhumbline Advisers increased its holdings in shares of Revance Therapeutics by 13.3% in the 1st quarter. Rhumbline Advisers now owns 49,124 shares of the biopharmaceutical company’s stock valued at $774,000 after acquiring an additional 5,785 shares during the period. Institutional investors own 94.86% of the company’s stock.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.
Further Reading: How to Track your Portfolio in Google Finance
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.